About Us

iSTAT Therapeutics is breaking resistance to cancer immunotherapy

By eliminating the “master brake" engaged by the tumor in multiple types of immune cells,  iSTAT's novel platform of bi-modal oligonucleotide drugs overcomes a key hurdle in achieving effective immunotherapy treatments across a variety of cancer types, independently of their genetic differences.